• Users Online: 1084
  • Home
  • Print this page
  • Email this page
RESEARCH AND REPORT
Year : 2014  |  Volume : 9  |  Issue : 5  |  Page : 489-497

Shuganjieyu capsule increases neurotrophic factor expression in a rat model of depression


1 Mental Health Institute of the Second Xiangya Hospital, Key Laboratory of Psychiatry and Mental Health of Hunan Province, Central South University; Department of Psychiatry, Brain Hospital of Hunan Province, Changsha, Hunan Province, China
2 Laboratory of Ethnopharmacology, Institute of Integrated Traditional Medicine and Western Medicine, the Second Xiangya Hospital, Central South University, Changsha, Hunan Province, China
3 Mental Health Institute of the Second Xiangya Hospital, Key Laboratory of Psychiatry and Mental Health of Hunan Province, Central South University, Changsha, Hunan Province, China
4 Guangzhou Brain Hospital, Affiliated Hospital of Guangzhou Medical College, Guangzhou, Guangdong Province, China
5 Department of Psychiatry, Brain Hospital of Hunan Province, Changsha, Hunan Province, China

Correspondence Address:
M.D. Jingping Zhao
Ph.D., Mental Health Institute of the Second Xiangya Hospital, Key Laboratory of Psychiatry and Mental Health of Hunan Province, Central South University, Changsha 410011, Hunan Province
China
Yong Liu
Ph.D., Mental Health Institute of the Second Xiangya Hospital, Key Laboratory of Psychiatry and Mental Health of Hunan Province, Central South University, Changsha 410011, Hunan Province
China
Login to access the Email id

Source of Support: Funding: This study was supported by the National Natural Science Foundation of China, No. 81071093, 81171268., Conflict of Interest: None


DOI: 10.4103/1673-5374.130067

Rights and Permissions

Shuganjieyu capsule has been approved for clinical treatment by the State Food and Drug Ad­ministration of China since 2008. In the clinic, Shuganjieyu capsule is often used to treat mild to moderate depression. In the rat model of depression established in this study, Shuganjieyu capsule was administered intragastrically daily before stress. Behavioral results confirmed that depressive symptoms lessened after treatment with high-dose (150 mg/kg) Shuganjieyu capsule. Immunohistochemistry results showed that high-dose Shuganjieyu capsule significantly increased phosphorylation levels of phosphorylation cyclic adenosine monophosphate response element binding protein and brain-derived neurotrophic factor expression in the medial prefrontal cortex and hippocampal CA3 area. Overall, our results suggest that in rats, Shuganjieyu capsule effec­tively reverses depressive-like behaviors by increasing expression levels of neurotrophic factors in the brain.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1306    
    Printed17    
    Emailed0    
    PDF Downloaded235    
    Comments [Add]    
    Cited by others 1    

Recommend this journal